Lack of research keeps end-of-life care in status quo

February 04, 2016

COLUMBIA, Mo. (Feb. 04, 2016) ? Randomized controlled trials often are considered the gold standard of research studies that help guide the medical care of patients across the world. However, in hospices, randomized controlled trials are difficult to conduct since patients are so close to the end of their lives, causing a gap in research that could improve the quality of hospice care overall. Now, a University of Missouri School of Medicine researcher has found that only 10 randomized controlled trials have taken place in U.S. hospices since 1985. The researcher said more randomized trials by hospice researchers could lead to improved care for hospice patients.

"Improving care for hospice patients and their families depends, at least in part, on conducting high-quality research in hospice settings," said Robin Kruse, Ph.D., research professor in the Department of Family and Community Medicine at the MU School of Medicine. "Research is how we make things better. Without research, we either maintain the status quo or implement programs that lack evidence."

Kruse and her colleagues analyzed all hospice research studies conducted between 1985 and 2015. They found only 10 hospice studies used randomized control trials, and none of the studies directly addressed managing pain, one of the most cited problems for hospice patients.

"Managing pain for hospice patients relies heavily on research conducted on other populations like cancer patients, with the assumption that treatments and results will be the same," Kruse said. "It's a common assumption among researchers that results from other pain studies can be applied to hospice patients, but without targeted studies specifically in hospices, no one can know for sure if those are the best practices for that specific group."

Kruse said there are several strategies researchers can use to conduct more successful studies in hospices, including building strong relationships between hospices and the research team, using research staff who are embedded in hospices and using electronic health records for patient data.

Overall, Kruse believes that if hospice researchers focused more on conducting randomized trials that do not place significant burdens on patients, families or hospice staff, it could lead to improved care for hospice patients. She encourages more researchers to address the gap of evidence-based results in hospice settings so these patients receive the best care possible in the last months or weeks of their lives.

Kruse's study, "Randomized Clinical Trials in U.S. Hospices: Challenges and the Current State of the Art," recently was published in Clinical Investigation, a journal focused on the progress and outcomes of clinical trials.
-end-


University of Missouri-Columbia

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.